RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $343
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $325 to $343.
August 04, 2023 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals and raised the price target from $325 to $343.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100